ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

BioNTech raises $325 million for mRNA therapy and more

by Ryan Cross
July 12, 2019 | APPEARED IN VOLUME 97, ISSUE 28

 

BioNTech, the German drug company best known for its experimental messenger RNA therapies, has raised $325 million in series B financing to move more of its drug candidates to the clinic and build up its manufacturing capacity. The fast-growing firm had raised about $500 million over the past 2 years from private investors and pharmaceutical collaborators. BioNTech says it needs the money to further build and test its experimental cancer immunotherapies, including antibodies, cell therapies, mRNA therapies, and small molecules.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment